8 April 2022 - The TGA has approved yet another adalimumab biosimilar.

Yuflyma from Celltrion is the seventh adalimumab biosimilar to be approved by the TGA. 

For the time being, only the 40 mg/0.4 mL solution in pre-filled syringes and pre-filled pens have been approved.

Read TGA prescription medicine decision summary for Yuflyma